Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.

Authors

null

Hui Li

Department of Thoracic/Head and Neck Medical Oncology, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX

Hui Li , Kang Qin , Zheng Zhang , Lingzhi Hong , Carol C. Wu , Myrna Cobos Barco Godoy , Mara Antonoff , Edwin J. Ostrin , Iakovos Toumazis , Don Lynn Gibbons , John Heymach , J. Jack Lee , Jia Wu , Jianjun Zhang

Organizations

Department of Thoracic/Head and Neck Medical Oncology, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of General Internal Medicine, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Thoracic/Head and Neck Medical Oncology, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Imaging Physics, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Thoracic/Head and Neck Medical Oncology, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

Institutional Funding
The University of Texas MD Anderson Lung Cancer Moon Shot Program

Background: With the wide use of CT for lung cancer screening and diagnosis, detection of pulmonary nodules increases drastically. Brock malignancy risk scoring is a validated risk prediction model for distinguishing malignant nodules, but it only provides a snapshot without incorporating the dynamic changes of lung nodules. Our study tested the performance of Brock malignancy risk scoring system in patients with persistent lung nodules. Methods: We prospectively studied a cohort of 304 patients with persistent lung nodules (at least 2 CT scans, 3 months apart with no evidence of shrinkage) who were under management at MD Anderson Cancer Center from 11/28/2018 to 12/14/2022. These lung nodules were assessed by radiologists with Brock full model. These patients were followed up routinely and subjected to biopsy as determined by treating physicians. The area under the receiver operating characteristic curve (AUC) and the optimal cut-off of Brock model was studied. Additionally, we studied another cohort with 130 patients with histologically confirmed lung cancer. We retrospectively reviewed the CT or PET/CT scans and assessed the corresponding persistent lung nodules as defined above prior to the cancer diagnosis. We explored the correlations among nodule characteristics, demographic factors and Brock cancer risk scores. Cox proportional hazards model was built for multivariate analysis. Results: The median follow-up time for the prospective cohort was 337 days and 40 of the 304 patients (13.16%) were diagnosed with lung cancer with a median lung cancer-free survival of 228 days. The mean risk score was 24.20% (0.12%-62.86%) for histologically confirmed malignant vs 11.01% (0.07%-61.84%) for the remaining lung nodules (P < 0.001). Of note, 4 of 46 (8.70%) patients with persistent lung nodules of risk scores between 5%-10% and 8 of 134 (5.97%) patients with risk score < 5% were diagnosed with lung cancer. The AUC for Brock model was 0.72 and the optimal cut-off value is 10.64% (sensitivity: 0.702, specificity:0.677). Among the retrospective cohort of 130 lung cancer patients (82.3% adenocarcinoma, 13.1% squamous cell carcinoma and 4.6% others), the predicted risk score ranged from 0.09% to 85.82%, including 33.85% of patients with risk score < 10% and 26.15% of patients with predicted risk score < 5%. The risk score was not correlated with age, sex, race, ethnicity, smoking history, family history of lung cancer, emphysema, nodule types or locations. The low-risk patients had a longer median cancer-free time (P = 0.001). Conclusions: Persistency is an important risk factor for malignant lung nodules. Using Brock criteria, a substantial proportion of lung nodules with true malignant potential can be overlooked because of predicted “low risk”. Improved prediction models incorporating the dynamic changes of lung nodules are warranted to guide early diagnosis of lung cancer.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8569)

DOI

10.1200/JCO.2023.41.16_suppl.8569

Abstract #

8569

Poster Bd #

196

Abstract Disclosures

Similar Abstracts

First Author: Matthew Smeltzer

Abstract

2022 ASCO Annual Meeting

Incidental pulmonary nodules, lung cancer screening, and lung cancer in the Medicare population.

First Author: Raymond U. Osarogiagbon

Abstract

2023 ASCO Annual Meeting

Multicenter evaluation of AI-based CT radiomics for EGFR mutation prediction in NSCLC.

First Author: Yan Liu